

**PROGRESSIVE'S EVENING STROLL**

**DATE: 27 March, 2023**

**Market Snapshot:**

Divergence was seen in today's session where Broader market kept on correcting while with the help of the heavyweight counters, Index managed to hold its gains to end the session at 16,985.70 with gains of 40.65 points. Up-move in the Index was primarily supported by the Pharma stocks. Stock specific buying was witnessed in the FMCG & Metal sectors.

**HOW THE DAY TRENDED**



INDICES			
Index	Close	Points	% Chg
Sensex	57653.86	126.76	0.22
Nifty	16985.70	40.65	0.24
Nifty Midcap 100	29426.60	(138.85)	(0.47)
Nifty Small Cap 100	8781.65	(142.25)	(1.59)

SECTORAL GAINERS / LOSERS			
Sectors	Close	Points	% Chg
NIFTY PHARMA	11882.75	127.40	1.08
NIFTY FMCG	45188.00	128.00	0.28
NIFTY MEDIA	1677.35	(18.30)	(1.08)
NIFTY REALTY	376.55	(4.40)	(1.16)

NIFTY TOP GAINERS / LOSERS					
Gainers	CMP (Rs)	%chg	Losers	CMP (Rs)	% Chg
GRASIM	1623.90	1.86	ADANI PORTS	626.85	(1.75)
RELIANCE	2238.80	1.61	SBI LIFE	1099.40	(1.15)
CIPLA	889.55	1.40	POWER GRID	219.90	(1.12)
DIVIS LABS	2833.00	0.93	ADANI ENT	1721.35	(1.11)

**INDICES LEVELS FOR March 28, 2023**

Nifty (future)	
Resistance	17,250
Support	16,920

Bank Nifty (future)	
Resistance	39,960
Support	39,040



**KEY TAKEAWAYS OF THE DAY**

◆ **Sun Pharma to foray into Animal Healthcare with Rs143cr acquisition:**

Sun Pharmaceutical Industries Ltd. has entered into an agreement to acquire a 60% stake in Vivaldis Health and Foods Pvt., a company in the animal healthcare space. Sun Pharma is acquiring the stake for a cash consideration of Rs143.3cr from existing shareholders, with the remaining 40% to be acquired in the future on the basis of certain terms and conditions. The acquisition is expected to be completed by the end of May. Vivaldis Health And Foods is engaged in the business of manufacturing and marketing of drugs, food supplements and over-the-counter products in the companion animal segment of the animal healthcare industry.

◆ **Alembic Pharmaceuticals receives 2 observations for Gujarat facility from USFDA:**

The United States Food and Drug Administration has conducted an inspection at Alembic Pharmaceuticals' injectable and ophthalmic facility (F-3) at Karkhadi during March 16-24. The USFDA has issued a Form 483 with 2 minor procedural observations. None of the observations are related to data integrity and management.

◆ **Sunil Singhania's Abakkus picks stake in TTK Healthcare via block deal:**

Sunil Singhania led asset management firm Abakkus Asset Manager LLP bought 131,788 equity shares of TTK Healthcare at an average price of Rs911.08 apiece. While, Abakkus Diversified Alpha Fund bought 115,385 shares at an average price of Rs910 per share on the BSE, as per bulk deals data available on the exchange. The total value of this stake is Rs22.5cr. MCap India Fund, managed by Gurgaon-based private equity firm MCap Fund advisors offloaded the shares.

◆ **BEL secures orders worth Rs4,300cr from Indian Army, Indian Navy:**

The Ministry of Defence (MoD), Govt of India, has signed a contract worth Rs3000cr with Bharat Electronics (BEL) for supply of 'integrated electronic warfare systems' for the Indian Army. Further, BEL has also received several contracts totalling approximately to Rs1300cr during last fortnight from the Indian Navy for supply of Indigenously developed fire control, gun fire control, surveillance, tracking, ESM, sonar systems etc.

◆ **NBCC arm bags order from AIIMS for Rs81cr:**

Subsidiary HSCC (India) has received work order worth Rs 81.19 crore from All India Institute of Medical Sciences (AIIMS), New Delhi. HSCC will construct vertical expansion of service block (1st Floor to 9th Floor), at AIIMS Campus. The project period is 18 months from the date of commencement work.

**Source: Media Reports**



**DISCLAIMERS AND DISCLOSURES:**

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research Analyst has served as officer, director or employee of the subject company: NO

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

**Terms & Conditions:**

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

**Registered Office Address:**

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai—400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500.

**Compliance Officer:**

Mr. Shyam Agrawal  
Email: compliance@progressiveshares.com  
Contact No.:022-40777500.

